Compare Anheuser-Busch Inbev SA (BUD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Eli Lilly And Co — how do they compare? Anheuser-Busch Inbev SA trades at $79.97 (market cap $163.79B), while Eli Lilly And Co trades at $1,215.25 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 6.7× Anheuser-Busch Inbev SA's market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| BUD | LLY | |
|---|---|---|
Market Cap | $163.79B | $1.10T |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $1.24K |
52-Week Low | $57.93 | $639.43 |
Enterprise Value | $228.20B | $1.14T |
Dividend Yield | 1.62% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.76, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $90.17. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 expected, while revenue trends show modest growth, and net income margin improved to 11.52% in 2025. Cash flow remains positive, and debt-to-asset ratios have declined steadily since 2021.
The outlook is positive given strong analyst buy ratings (57.78%) and projected earnings growth, but risks include competitive pressures and macroeconomic sensitivity. The stock offers value with a P/E of 18.05 and stable profitability, though investor sentiment is mixed amid recent institutional selling and news of a major shareholder divestment.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
